News

Luminoah Announces FDA Clearance of the Luminoah Flow Enteral Nutrition System, A Brighter Future for Tube Feeding

Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug Administration clearance for Luminoah Flow™, an enteral feeding system designed to improve the experience of patients who rely on tube feeding.

Luminoah Flow combines portability, precision, and connected technology into a streamlined system designed for both patients and clinicians. It provides access to real time data, simplifies workflows, and features a design intended to improve mobility and independence.

For Luminoah founder Neal Piper, this milestone reflects six years of innovation shaped by personal experience with enteral nutrition during his son’s cancer treatment.

“FDA clearance of Luminoah Flow marks a major milestone in our mission to transform enteral nutrition,” said Neal Piper, Founder and Chief Executive Officer of Luminoah. “Inspired by my family’s experience, we built Luminoah to address persistent challenges faced by patients and caregivers. Patients living with feeding tubes need solutions that integrate more naturally into daily life, and Luminoah Flow brings together modern technology and patient centered design to better support patients, caregivers, and clinicians.”

“One of the biggest gaps in enteral care today is limited visibility once patients leave the hospital,” said Dr. Gary Nace Jr., Pediatric Surgeon at Children’s Hospital of Philadelphia. “Clinicians often rely on reported information rather than objective data when managing nutrition outside the hospital. A system like Luminoah Flow may help provide greater visibility into what is being delivered at home and support more informed clinical decision making.”

“Enteral nutrition is a critical therapy for millions of patients, yet the technology supporting it has changed very little over time,” said Tegan Medico, MS, MPH, RDN, CNSC, Clinical Dietitian at UVA Health. “Much of the burden still falls on patients and caregivers to manage feeds and communicate what is happening at home. A system like Luminoah Flow may help bring greater simplicity and visibility to that process, allowing clinicians to better support patients between visits.”

Key Features of Luminoah Flow Include:

  • Compact, lightweight design that enhances mobility and discretion

  • Real time data tracking to support visibility into nutrition delivery

  • Modern touchscreen pump interface for both patients and caregivers

  • Eco-friendly USB-C charging capability for flexibility and convenience

“This clearance reflects the work our team has put into solving a deeply important problem,” said Garrett Marin, Chief Operating Officer at Luminoah. “We are excited to bring a solution to market that meets regulatory standards while improving day to day care for patients and providers.”

Luminoah plans to begin a phased commercial rollout of Luminoah Flow across the United States, working closely with healthcare providers, home health organizations, and patient communities.

Read more here.

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …